Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists-Reference-Cited by-同舟云学术

Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists

Published:2021-04 Issue:4 Volume:9 Page:254-264
ISSN:2213-1779
Container-title:JACC: Heart Failure
language:en
Short-container-title:JACC: Heart Failure

Author:

Shen Li,Kristensen Søren Lund,Bengtsson Olof,Böhm Michael,de Boer Rudolf A.,Docherty Kieran F.,Inzucchi Silvio E.,Katova Tzvetana,Køber Lars,Kosiborod Mikhail N.,Langkilde Anna Maria,Lindholm Daniel,Martinez M. Felipe A.,O’Meara Eileen,Nicolau Jose C.,Petrie Mark C.,Ponikowski Piotr,Sabatine Marc S.,Schou Morten,Sjöstrand Mikaela,Solomon Scott D.,Jhund Pardeep S.,McMurray John J.V.

Funder

British Heart Foundation

AstraZeneca

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference24 articles.

1. Sodium glucose cotransporter-2 inhibition and cardiorenal protection: JACC Review Topic of the Week;Cherney;J Am Coll Cardiol,2019

2. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015

3. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N Engl J Med,2017

4. Dapagliflozin and cardiovascular outcomes in type 2 diabetes;Wiviott;N Engl J Med,2019

5. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist;Vardeny;Circ Heart Fail,2014

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In-hospital initiation of sodium-glucose cotransporter-2 inhibitors in patients with heart failure and reduced ejection fraction: 90-day prescription patterns and clinical implications;Current Problems in Cardiology;2024-10

2. Clinical characteristics and outcomes of patients aged 80 years and over with heart failure: Need for better treatment;European Journal of Heart Failure;2024-08-21

3. Non-acute heart failure management in primary care;BMJ;2024-04-05

4. SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review;Diabetes Therapy;2024-04-05

5. Real-world evidence of the effects of sodium-glucose co-transporter 2 inhibitors on the dosing of diuretics in patients with heart failure: a retrospective cohort study;Frontiers in Pharmacology;2024-04-02